Urispas Medication Guide
Active Ingredient
Urispas contains an active ingredient called flavoxate hydrochloride. This compound is a type of urinary antispasmodic agent that relieves spasms of the urinary bladder muscle.
Available Forms
Urispas is available in tablet form, commonly in 100 mg and 200 mg dosages. Tablets should be stored at room temperature, protected from light and moisture, and kept out of reach of children.
Intended Use
Urispas is primarily used to treat symptoms such as painful urination, urgency, frequency, and nocturia associated with various bladder conditions including cystitis, prostatitis, and urethritis. It helps relieve bladder spasms and discomfort.
Mechanism of Action
Flavoxate hydrochloride works by inhibiting phosphodiesterase enzyme and reducing the contractility of the smooth muscle in the urinary bladder, leading to decreased spasms and relaxation of the bladder muscle.
Dosage and Administration
The recommended adult dosage of Urispas is typically one 100 mg or 200 mg tablet three to four times daily. The dosage may be adjusted by a healthcare professional based on individual patient response and clinical condition.
Onset and Duration
The onset of action for Urispas typically occurs within an hour of oral administration, with the effects lasting for approximately 3-4 hours. Patients should follow the prescribed schedule for optimal results.
Special Populations Considerations
For elderly patients, dose adjustments may be necessary due to age-related physiological changes. Caution should also be exercised with patients having underlying medical conditions such as liver or renal impairment.
Drug Interactions
Urispas may interact with other medications, including anticholinergic agents, as their combination could enhance anticholinergic effects. It may also interact with other medications metabolized in the liver. Always disclose all current medications to the healthcare provider before starting Urispas.
Pediatric Use
The safety and efficacy of Urispas in children under the age of 12 have not been established. Pediatric usage should be under strict medical supervision when necessary.
Pregnancy and Lactation
Urispas falls under Pregnancy Category B. While animal studies do not indicate direct harm to the fetus, it should only be used in pregnancy if clearly needed. It is unknown if flavoxate is excreted in human breast milk; thus, caution is advised during breastfeeding.
Side Effects
Common side effects of Urispas include dry mouth, drowsiness, blurred vision, dizziness, and gastrointestinal disturbances such as nausea or vomiting. Serious side effects may include allergic reactions, difficulty urinating, or severe dizziness.
Contraindications
Urispas is contraindicated in patients with hypersensitivity to flavoxate hydrochloride or any of the excipients in the formulation. It is also contraindicated in patients with gastrointestinal obstruction, intestinal atony, or obstructive uropathies.
Monitoring Parameters
Monitoring may include assessment of urinary symptoms, renal function, and checking for any adverse reactions. Regular follow-up visits with healthcare providers are recommended to ensure the medication efficacy and safety.
Administration Instructions
Urispas tablets should be taken with a full glass of water, and they can be taken with or without food. Drinking adequate fluids is encouraged unless otherwise directed by a healthcare provider. Do not crush or chew the tablets.
Storage Requirements
Keep Urispas tablets in their original container, tightly closed when not in use. Store at controlled room temperature, between 20-25°C (68-77°F), away from excessive heat and moisture. Ensure the medication is inaccessible to children.
Missed Dose Protocol
If a dose of Urispas is missed, take it as soon as remembered. However, if it is almost time for the next dose, skip the missed dose. Do not double the dose to catch up; this can increase the risk of side effects.
Overdose Management
In case of an overdose, seek immediate medical attention or contact a poison control center. Symptoms of overdose may include severe drowsiness, dizziness, or difficulty breathing. Do not attempt to self-treat an overdose.
Long-term Use
The necessity of prolonged use of Urispas should be regularly reviewed by a healthcare provider due to potential adaptation of the urinary system to the drug and to avoid long-term side effects. Adjustments or discontinuation should be managed by a healthcare professional.
Patient Counseling Information
Patients taking Urispas should be advised on possible side effects, the importance of adherence to prescribed doses, and notifying their healthcare provider of any new symptoms or worsening condition. They should also be informed about the potential for dizziness and advised against operating heavy machinery if affected.